A major strength of this review is the inclusion of clinical studies involving diverse patient cohorts (CAVD, MI, SLE, Type 2 diabetes) presenting elevated circulating leptin levels as well as animal studies ranging from global to cell-specific transgenic murine models. The gene discussed is LEP; the disease is type 2 diabetes mellitus.